Michelle Dipp, M.D., Ph.D. is an entrepreneur, and advocate for fertility innovation. She is Executive Chair of the Board of Directors of OvaScience, a global fertility company dedicated to improving treatment options for women around the world. Dr. Dipp co-founded OvaScience in 2011 and served as its Chief Executive Officer through June 2016. Dr. Dipp is also a Founder and Partner of Longwood Fund, a healthcare venture capital firm that founds and invests in healthcare companies. Dr. Dipp is a frequent keynote speaker on the topic of fertility innovation and its significance in modern society, given her background which spans science, corporate development and entrepreneurship. She has spoken at the World Economic Forum in Davos, Summit Series, Fortune’s Most Powerful Women Summit, and the JP Morgan Healthcare Conference. In March 2015, Dr. Dipp was elected to join the World Economic Forum’s Young Global Leaders. In September 2015, Dr. Dipp was named to Fortune Magazine's 40 Under 40 list. Prior to co-founding OvaScience, Dr. Dipp was the Senior Vice President and Head of the Centres for Excellence in Drug Discovery at GlaxoSmithKline (GSK). Prior, Dr. Dipp was the Vice President of Corporate Development at Sirtris, which developed new drug candidates that target the sirtuins. Dr. Dipp serves on the Biotechnology Industry Organization’s Emerging Companies Governing Board, the Beth Israel Deaconess Medical Center Board of Directors, the Boston Symphony Orchestra Board of Overseers, and the NEVCA Board of Directors. Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.